Pictet Asset Management Holding SA Sells 88,382 Shares of Grifols, S.A. (NASDAQ:GRFS)

Pictet Asset Management Holding SA reduced its stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 3.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,626,603 shares of the biotechnology company's stock after selling 88,382 shares during the quarter. Pictet Asset Management Holding SA owned 0.38% of Grifols worth $19,542,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GRFS. R Squared Ltd bought a new stake in shares of Grifols in the fourth quarter valued at about $28,000. GAMMA Investing LLC grew its stake in shares of Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 1,527 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 4,970 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in shares of Grifols in the fourth quarter worth $77,000. Finally, Raymond James Financial Inc. acquired a new position in Grifols during the fourth quarter worth $91,000.

Analysts Set New Price Targets

Separately, Morgan Stanley began coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock.

Remove Ads

Grifols Stock Performance

Shares of GRFS stock traded down $0.50 on Friday, reaching $6.62. The stock had a trading volume of 783,032 shares, compared to its average volume of 1,231,967. Grifols, S.A. has a 12 month low of $5.79 and a 12 month high of $9.96. The firm has a market capitalization of $4.55 billion, a price-to-earnings ratio of 5.65 and a beta of 0.35. The firm's 50-day moving average is $7.54 and its two-hundred day moving average is $8.00. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.